This will allow uniform inclusion of MDS/MPN patients with RS in future clinical trials with novel drugs focused on reversing erythroid arrest such as TGFβ modulators, splicing inhibitors among others [18–20]. This evidence concerns the gene TGFB1 and myeloproliferative disorder.